Influence of recombinant erythropoietin on mesenchymal stem cells proliferation and differentiation during cultivation on allogenic bone matrix by Nadezhdin, Sergey V. et al.
310
Influence of recombinant erythropoietin 
on mesenchymal stem cells proliferation 
and differentiation during cultivation 
on allogenic bone matrix
Sergey V. Nadezhdin1, Ekaterina V. Zubareva1, Anatoliy V. Ovsyankin2, Svetlana A. Guzyukina2, Elena A. Atamanyuk3, Ekaterina S. Gnezdyukova4, Kseniya R. Zhukovskaya4
1Belgorod National Research University, 308015, Russia, Belgorod, Pobedy St. 85; https://orcid.org/0000-0001-7215-295X 
1Belgorod National Research University, 308015, Russia, Belgorod, Pobedy St. 85; https://orcid.org/0000-0002-9557-145X 
2Federal State Budgetary Institution “Federal Center for Traumatology, Orthopedics and Endoprosthetics” of the Ministry of Health of the Russian Federation. 214031, 
Russia, Smolensk, Stroiteley Ave. 29; https://orcid.org/0000-0002-0779-091X 
2Federal State Budgetary Institution “Federal Center for Traumatology, Orthopedics and Endoprosthetics” of the Ministry of Health of the Russian Federation. 214031, 
Russia, Smolensk, Stroiteley Ave. 29; https://orcid.org/0000-0001-5652-9489 
3Regional State Budgetary Institution of Health “Belgorod Regional Clinical Hospital of St. Ioasaph”. 308007, Russia, Belgorod, Nekrasova St. 8/9; 
https://orcid.org/0000-0002-4095-9473 
4Belgorod National Research University, 308015, Russia, Belgorod, Pobedy St. 85; https://orcid.org/0000-0002-1672-3495 
4Belgorod National Research University, 308015, Russia, Belgorod, Pobedy St. 85; https://orcid.org/0000-0002-2835-0630 
*corresponding author: Sergey V. Nadezhdin, Belgorod National Research University, 308015, Russia, Belgorod, Pobedy St. 85. Email: nadezhdin@bsu.edu.ru 
Influencia de la erytropoietina recombinante en la proliferación y diferenciación de células madre mesequímicas 














ffectiveness of mesenchymal stem cells 
(MSCs) proliferation and differentiation was 
studied after addition of medicinal product 
containing human recombinant erythropoietin (rhEPO) 
into enriched culture medium with components for osteo- 
and angiogenesis. Cultivation of mesenchymal stem cells 
under static conditions using “cocktail” of growth factors 
and rhEPO allowed to populate allogenic discs-scaffolds 
with connective tissue formations with the participation 
of osteoblasts and elongated multicellular structures, 
which formed after endothelium-like cells fusion. In the 
presence of rhEPO MSCs differentiates more effectively in 
osteogenic direction than in angiogenic.
Keywords: mesenchymal stem cells (MSCs), recombinant 
erythropoietin, allogenic bone matrix, proliferation, differ-
entiation.
a efectividad de la proliferación y diferen-
ciación de las células madre mesenquimales 
(MSC) se estudió después de la adición de un 
medicamento que contiene eritropoyetina recombinante 
humana (rhEPO) en un medio de cultivo enriquecido con 
componentes para osteo- y angiogénesis. El cultivo de 
células madre mesenquimáticas en condiciones estáticas 
utilizando un “cóctel” de factores de crecimiento y rhEPO 
permitió poblar los andamios-discos alogénicos con for-
maciones de tejido conectivo con participación de osteo-
blastos y estructuras multicelulares alargadas, que se for-
maron después de la fusión de células de tipo endotelio. 
En presencia de rhEPO, las MSC se diferencian más eficaz-
mente en la dirección osteogénica que en la angiogénica.
Palabras clave: Células madre mesenquimales (MSC), 
eritropoyetina recombinante, matriz ósea alogénica, proli-
feración, diferenciación.
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ecent advances in biotechnology allowed 
to synthesize and produce in an industrial 
large-scale human recombinant erythro-
poietin (rhEPO, epoetin)1 and its analogs (erythropoiesis-
stimulating agents (ESAs))2-4 to use as medicinal products 
for treatment of various diseases5,6, rhEPO was charac-
terized as hematopoietic and tissue-protective factor3,7,8, 
and besides the properties similar to vascular endothelial 
growth factor (VEGF) were revealed6. It was discovered 
that erythropoietin could stimulate endothelial cells pro-
liferation in vitro and mobilize endothelial progenitor cells 
from the bone marrow9-11, promote circulating endothe-
lial progenitor cells adhesive and proliferative properties12. 
In most research papers it is stated that erythropoietin 
triggers mesenchymal stem cell differentiation into osteo-
blasts in vitro and stimulation of bone tissue formation oc-
curs because of increased VEGF expression13-16. This raises 
the question: does erythropoietin induce mesenchymal 
stem cell differentiation into osteoblasts or endothelio-
cytes predominantly?
Aim: The research aimed to study the effectiveness of 
mesenchymal stem cells proliferation and direction of 
their differentiation after the addition of erythropoietin 
into culture medium containing supplements for osteo- 
and angiogenesis.
 
he experiment was divided into three parts: dur-
ing the first part proliferative activity of cells was 
investigated (6 samples), at the second and the 
differentiation of the third parts of MSCs was studied in 
osteogenic (6 samples) and angiogenic directions (n=6) 
respectively. To perform the study at each part control and 
experimental groups were formed. Tests performed in 
triplicates for each group. The cells from the control group 
were cultured on bone discs-scaffolds in growth medium 
containing osteogenic and endotheliogenic supplements. 
The cells from the experimental group were cultured on 
bone discs-scaffolds in growth medium containing osteo-
genic and endotheliogenic supplements and recombinant 
human erythropoietin.
After the end of the cultivation period at the first part of 
the experiment proliferative activity of hAT-MSCs which 
were grown on bone, discs-scaffolds was studied using 
confocal laser scanning microscope DIGITAL ECLIPSE С1 
plus (Nikon, Japan) with a fluorescent probe – Сalcein AM 
(Invitrogen, USA). The solution was prepared and the time 
of cultivation was determined according to the manufac-
turer’s instructions. Fluorescent dye stock solution at a 
concentration of 5 mM was prepared in dimethyl sulfox-
ide (DMSO). 
During the second and the third parts of the experiment 
bone discs-scaffolds with cells were washed with phos-
phate-buffered saline (PBS) and fixed with 10% formalin 
solution for investigation of the direction of hAT-MSCs dif-
ferentiation. For these purposes, Osterix (a marker of hAT-
MSCs differentiation into osteoblasts) and CD31 (a marker 
of endothelial cells) were used. Software “Statistica 10” 
was used for statistical analysis of experimental data.
Main part: Study of hAT-MSCs, osteoblasts and endothe-
lial progenitor cells proliferative potential was performed 
via measuring of intensive proliferation centers areas be-
cause the cells at the 20th day of cultivation on the bone 
discs-scaffolds united in connective tissue structures. In-
crease of the area of new formed connective tissue struc-
tures in the experimental group (16406.93±235.92 mkm2) 
in comparison with the control group (15250.97±182.34 
mkm2) (р≤0.01) was revealed (Fig. 1).
During the analysis of fluorescent images, it was revealed, 
that after 20 days of cultivation on bone trabeculae and 
intertrabecular space of the experimental group samples 
connective tissue formations appeared which had been 
formed due to mesenchymal stem cells, osteoblasts, and 
endothelial progenitor cells proliferation. increase of 
connective tissue structures area formed by osteoblasts 
(fluorescent probe Osterix) was noted in the experimen-
tal group (17362.94±266.34 mkm2) in comparison with 
control (16274.89±247.98 mkm2) (р≤0.01) (Fig. 2.А). Be-
sides the bone, connective tissue formations elongated 
multicellular structures containing endothelial-like cells 
(fluorescent probe CD31) were discovered in the experi-
mental group samples. increase of the elongated multi-
cellular formations area was revealed in the experimental 
group (164.19±4.63 mkm2) in comparison with the con-
trol group (147.51±7.34 mkm2) (р≤0.01) (Fig. 2.B).
Thus, the addition of rhEPO to the culture medium con-
taining inducers of osteo- and angiogenesis leads to en-
hancement of MSCs proliferation and differentiation in 
comparison with the control group. This effect could be 
described because rhEPO is a pleiotropic growth factor 
which stimulates the proliferation of both mesenchymal 
and hematopoietic stem cells17.(reference 26 not valid)
Cultivation of mesenchymal stem cells in static conditions 
using “cocktail” of growth factors and medicinal prod-
uct which includes rhEPO allowed to load allogenic discs-
scaffolds with cells and accompanied by the formation of 
connective tissue formations with the participation of os-
teoblasts and elongated multicellular structures appeared 
























he addition of human recombinant erythro-
poietin into growth medium increases mesen-
chymal stem cells proliferation which accompa-
nied by the formation of connective tissue and 
elongated multicellular structures.
Differentiation of mesenchymal stem cells under the influ-
ence of recombinant human erythropoietin is more effi-
cient in osteogenic direction than in angiogenic direction.
Figure 1. Optical slices series. Fluorescence of new formed connective tissue structures in bone disc-scaffold 
at the 20th day of cultivation (experimental group from the first part of the study, cells were stained with 
Сalcein AM). (DIGITAL ECLIPSE С1 plus, Nikon, Japan, Х 200 magnification).
B
Figure 2. Fluorescence of connective tissue structures – elements of the osteoid matrix (red fluorescence) (experimental group from 
the second part of the study) and elongated multicellular formations (green fluorescence) on the bone trabecula of disc-scaffold 
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